BRAF and mixed neuronal-glial tumor: Ancillary molecular testing is occasionally helpful in further categorizing such tumors, though this cannot always be relied upon as glial/glioneuronal tumors also frequently harbor overlapping molecular alterations such as BRAF p.V600E.